|
|
 | | | |
- close
- close
- close
- close
NPS Pharmaceuticals (NPSP) |
StreetInsider.com
May 22
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/NPS+Pharmaceuticals+%28NPSP%29+Prices+6M+Common+Stock+Offering/8360563.html for the full story.
StreetInsider.com
May 20
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/NPS+Pharma+%28NPSP%29+Announces+6M+Common+Stock+Offering/8355381.html for the full story.
FiercePharma
May 9
Comment
NPS Pharmaceuticals ($NPSP) racked up the first quarterly score on its $295,000-a-year treatment for short bowel syndrome, claiming early traction for Gattex. To be sure, the numbers are small: 42 patients and 160 prescriptions in Q1.
StreetInsider.com
May 9
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/NPS+Pharmaceuticals%2C+Inc.+%28NPSP%29+Posts+Q1+Loss+of+9cShare/8320859.html for the full story.
Forbes
May 7
Comment
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (AMEX: XBI) where we have detected an approximate $15.8 million dollar outflow -- that's a 1.9%...
Benzinga
Apr 24
Comment
In a report published Tuesday, Oppenheimer analyst Boris Peaker initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Outperform rating and $18.00 price target.
In the report, Peaker noted, “NPS is a biopharmaceutical company with...
TheStreet.com
Apr 3
Comment
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's "Mad Money" on CNBC:
WM data by...
Benzinga
Mar 20
Comment
Wedbush reiterated NPS Pharmaceuticals (NASDAQ: NPSP) with an Outperform rating and raises the price target from $19.00 to $22.00.
Wedbush analyst David Nierengarten noted, "NPSP announced the buy-back of ex-US rights from Takeda for Gattex...
TheStreet.com
Mar 20
Comment
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Tuesday's "Mad Money" on CNBC:
HTZ data by...
FiercePharma
Mar 19
Comment
NPS Pharmaceuticals thinks going solo on Gattex marketing can deliver bigger bucks for its top line. The company struck an $80 million deal to buy back ex-U.S. rights to the short-bowel syndrome drug from Takeda. Report
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
